79. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J (2006) The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 5: 1983–1988. 80. Bast RC, Jr., Mills GB (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28: 3545–3548. 81. Martin SA, Lord CJ, Ashworth A (2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18: 80–86. 82. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, et al. (2009) Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 69: 984–991. 83. Gmeiner WH, Reinhold WC, Pommier Y (2010) Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 9: 3105–3114. 84. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, et al. (2009) Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 8: 1037–1044. PARP Inhibitors Sensitize to Floxuridine 85. Kammler S, Lykke-Andersen S, Jensen TH (2008) The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells. Mol Cancer Res 6: 990–995. 86. Cao D, Pizzorno G (2004) Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 40: 431–443. 87. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM (1991) A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68: 1903–1909. 88. Pizzorno G, Sun Z, Handschumacher RE (1995) Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 49: 553–557. 89. Yin MB, Rustum YM (1991) Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition. Cancer Commun 3: 45–51. PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28862